Congestive Heart Failure

Collateral Announces Issuance of Patent Directed To Gene Therapies

Published in Gene Therapy Weekly, November 22nd, 2001

Collateral Therapeutics, Inc., (CLTX) has been issued U.S. Patent No. 6,306,830, "Gene Therapy for Congestive Heart Failure" by the U.S. Patent and Trademark office. The patent relates to methods of in vivo gene transfer via nonsurgical administration for the potential treatment of congestive heart failure, and the technology it covers was exclusively licensed by the company from the University of California.

The patent is directed to methods employing a gene delivery vector and a therapeutic gene encoding a beta-adrenergic signaling element, particularly a cardiac adenylylcyclase (AC) gene to enhance cardiac function for patients with congestive heart failure. In the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry